Intermountain Healthcare, a Utah-based not-for-profit integrated delivery network of hospitals, clinics, a health plan and other medical services, has selected Elsevier's Via Oncology to provide clinical pathways for Intermountain's Oncology Clinical Program.
Via Oncology's Via Pathways helps cancer centers demonstrate the value of their care to patients, referring physicians and payers, by developing and implementing clinical pathways in collaboration with its network of more than 1,500 US cancer care providers. Via Oncology's Via Pathways includes evidence-based proprietary content developed by committees composed of leading oncologists that forms the basis of clinical algorithms covering 95 percent of cancer types treated in the US.
Via Oncology's evidence-based proprietary content is deployed to physicians and their staff at the point of care through the Via Portal, a patient-specific decision support tool that is integrated with the electronic medical record and provides seamless measurement of adherence. Via Pathways addresses more than 2,000 unique patient presentations, including expert-defined clinical algorithms and specific recommendations for all significant aspects of cancer care.
Intermountain's Oncology Clinical Program has a system role to ensure optimal cancer care delivery. Intermountain's cancer disease-specific development teams conduct quality improvement and cancer care delivery research designed to improve treatment options and outcomes for cancer patients, while reducing system variation and cost.
Elsevier recently acquired Pittsburgh, Pennsylvania-based Via Oncology, a former subsidiary of UPMC (University of Pittsburgh Medical Center), one of the nation's leading integrated healthcare delivery and financing systems.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
